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Objective: To investigate the prevalence and predictors of COPD in a large cohort of
symptomatic smokers and ex-smokers in a primary care setting.
Methods: General practitioners (n=390) consecutively recruited individuals ≥35 years, with
current or previous tobacco exposure, at least one respiratory symptom, and no previous
diagnosis of obstructive airways disease; and obtained data on tobacco exposure, body mass
index (BMI), and dyspnea (Medical Research Council dyspnea scale). All individuals with
airﬂow obstruction, ie, FEV1/FVC <0.70 at initial lung function test, had diagnostic spirometry,
including bronchodilator reversibility test. COPD was deﬁned as respiratory symptom(s),
tobacco exposure, and nonreversible airﬂow limitation.
Results: Of the 6,710 at-risk individuals screened with spirometry (52% male sex, mean age
58 years [SD 10.9]), 1,185 were diagnosed with COPD (17.7%). Apart from age and pack-
years, multivariate logistics regression analysis, adjusted for FEV1, revealed that BMI <25
kg/m2 (OR 4.2, 95% CI 3.0–5.9, p<0.001), BMI 35+ kg/m2 (OR 1.6, 95% CI 1.2–2.3), self-
reported dyspnea (OR 1.2, 95% CI 1.1–14, p=0.04), wheeze (OR 1.3, 95% CI 1.1–1.6,
p=0.001), phlegm (OR 1.4, 95% CI 1.1–1.6, p<0.001), and MRC ≥3 (OR 1.6, 95% CI 1.2–
2.0, p=0.001) were associated with a signiﬁcantly higher likelihood of being diagnosed with
COPD. No association was found between sex, cough, and recurrent respiratory tract
infections and a diagnosis of COPD.
Conclusion: The prevalence of COPD is high among smokers and ex-smokers with one or
more respiratory symptoms seen in primary care, and the presence of wheeze, phlegm and
dyspnea, together with both low BMI and obesity identify a subgroup with an even higher
likelihood of COPD.
Keywords: early COPD, general practice, screening, lung function tests, reversibility
Introduction
COPD has a signiﬁcant impact on life expectancy worldwide, illustrated by a close
to 10% increase in mortality from 2000 to 2015.1 Despite increasing public aware-
ness and more advanced treatment options, according to estimates made by the
European Respiratory Society, the proportion of deaths caused by COPD will
continue to increase both worldwide and in Europe until at least 2030.2
COPD is often diagnosed late in the course of the disease.3 A way to counteract
this may be secondary prevention by early diagnosis and intervention, as smoking
cessation is an effective way to slow the decline in lung function as well as the
progression of respiratory symptoms.4,5 One way to achieve this goal may be
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systematic screening for COPD in general practice, as
previous studies have revealed a high prevalence of
undiagnosed COPD among individuals at high risk due
to symptoms and tobacco exposure.3,6 Furthermore, in
many countries, the general practitioners (GPs) serve as
gatekeepers for referral to secondary care management. It
is therefore of utmost importance that GPs have not only
awareness but also tools to identify individuals at risk
requiring further diagnostic workup.
The present study was based on a pooled analysis of
data from two studies of opportunistic screening for COPD
in primary care. The primary aim was to investigate the
prevalence of undiagnosed COPD among symptomatic
smokers and ex-smokers. The secondary aim was to iden-
tify predictors of COPD in this high-risk group.
Materials and methods
Study design
This is a pooled analysis of data obtained from two similar
studies of screening at-risk individuals for COPD in pri-
mary care.7,8 Each of the studies aimed to include 5% of
the Danish GPs, ie, approximately 200 GPs for each of the
studies from all over Denmark. This strategy allows a
representative sample of the Danish population. The GPs
were asked to recruit and examine at least 20 subjects from
their own practice who met all the inclusion criteria and
none of the exclusion criteria. All procedures were per-
formed by the GP in his/her practice. In the study by
Kjeldgaard et al, the GPs were trained in the use of
COPD-6 screening device, but for all other measurements
in the studies, the participating GPs used their own
equipment.7
Study population
All eligible individuals fulﬁlled the following criteria: 1)
age ≥35 years, 2) current smoker or ex-smoker, 3) at least
one of the following respiratory symptoms: dyspnea,
cough, wheeze, sputum and recurrent lower respiratory
tract infections, and none of the exclusion criteria: 1)
inability to perform spirometry or 2) being previously
diagnosed with an obstructive lung disease, ie, asthma or
COPD.
All subjects had spirometry performed with at least
three forced expiratory maneuvers and at least two of
those differing <5% for highest obtained measurement of
both FEV1 and FVC. Spirometry was performed according
to spirometry guidelines from the Danish Respiratory
Society.9 In the study by Kjeldgaard et al, participants
were screened using the COPD-6 device before proceed-
ing, if indicated, to conﬁrmatory spirometry.7
Data on age, sex, height, body weight, smoking status,
number of years smoked, daily tobacco consumption, cur-
rent respiratory symptoms and severity of dyspnea accord-
ing to the Medical Research Council (MRC) Dyspnoea
scale10 (Table 1) were collected and entered into a con-
solidated web database. FEV1% predicted (European
Community of Steel and Coal reference values were used
for both studies), FVC, FEV1/FVC ratio, pack-years and
body mass index (BMI) were automatically calculated
based on the obtained data.7,8,11
Box 1
Grade
1. “I only get breathless with strenuous exercise”
2. “I get short of breath when hurrying on the level or up a
slight hill”
3. “I walk slower than people of the same age on the level
because of breathlessness or have to stop for breath when
walking at my own pace on the level”
4. “I stop for breath after walking 100 yards or after a few
minutes on the level”
5. “I am too breathless to leave the house”
Notes: 100 yards =91 m. Reproduced from: Medical Research Council. Medical
Research Council Dyspnoea scale. Available from: https://mrc.ukri.org/research/facil-
ities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathless-
ness-scale/. Used with the permission of the Medical Research Council.12
Table 1 Basic characteristics of the screened subjects (n=6,710)
divided according to COPD status
No COPD
(n=5,525)
COPD
(n=1,185)
p-value
Sex
Males 51.5% 53.8% NS
Age (years) 57.0 (11.7) 63.3 (10.6) <0.001
BMI (kg/
m2)
27.3 (5.0) 24.8 (5.0) <0.001
Smoking
CS 41.3% 34.7% <0.001
Pack-years 29.4 (20.9) 38.8 (22.5) <0.001
FEV1 (L) 2.8 (0.8) 1.9 (0.7) -
FEV1/FVC 0.8 (0.1) 0.6 (0.1) -
FEV1%pred 92.0 (17.0) 66.9 (18.3) -
Notes: Data shown as mean (SD).
Abbreviations: BMI, body mass index; CS, current smoker; NS, nonsigniﬁcant.
Katsimigas et al Dovepress
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Diagnostic algorithm
Participants with airway obstruction (FEV1/FVC <0.70)
at the initial spirometry had a bronchodilator reversibility
test performed with 0.4 mg of inhaled salbutamol (or
equivalent) followed by repeated spirometry 15 mins
later. Based on the increase in FEV1, participants with
an increase of ≥500 mL were classiﬁed as having asthma
and excluded from further analyses. For a more detailed
description of the methods see the papers by Lokke et al
and Kjeldgaard et al.3,7
COPD was deﬁned as respiratory symptoms, tobacco
exposure and nonreversible airﬂow limitation, ie, post-
bronchodilator FEV1/FVC ratio <0.70.
13
Statistics
Statistical analyses were performed with the software
SPSS v. 27.0 (IBM). The analyses were limited to partici-
pants with complete data. Data were tested for normality,
and nonparametric tests were used to analyze continuous
data. Categorical data were analyzed by the Mann–
Whitney U-test. In all statistical analyses, a two-tailed
p-value of ≤0.05 was considered signiﬁcant. Multivariate
logistic regression analysis was used to evaluate predictors
for a diagnosis of COPD and reported as odds ratios with
95% conﬁdence intervals and p-values. In the latter ana-
lyses, participants were stratiﬁed according to BMI into
three groups, ie, BMI <25 kg/m2, BMI >35 kg/m2 and the
remaining participants as the reference group.
Ethics
Both studies were endorsed by the Danish College of
General Practitioners. According to the European
Federation of Pharmaceutical Industries and Associations
code and the Danish Association of the Pharmaceutical
Industry, both studies were nondrug, noninterventional
studies. Approval from the Danish Scientiﬁc Ethics
Committee and the Danish Medicines Agency were, there-
fore, not mandatory for the two studies, but they were
given all relevant study information. Data handling was
approved for both studies by the Danish Data Protection
Agency.
Results
Study cohort
A total of 390 GPs (approximately 11% of all Danish GPs)
from all parts of Denmark participated in the two studies
and recruited a total of 6,710 symptomatic individuals
(52% male sex, mean age 58 years [SD 10.9]), 60%
current smokers, mean number of pack-years 33 (SD
21.5) at risk of COPD.
Prevalence of respiratory symptoms and
COPD
The most common respiratory symptom was a cough, with
a presence in almost ¾ of individuals in both COPD and
non-COPD participants (Figure 1).
70%
45%
26%
14%
8%
74%
58%
39%
25%
10%
0%
10%
20%
30%
40%
50%
60%
70%
80%
Cough
(P=0.006)
Dyspnea
(P<0.001)
Phlegm
(P<0.001)
Wheeze
(P<0.001)
RLRTI
(P<0.001)
No COPD (n=5525) COPD (n=1185)
Figure 1 Prevalence of respiratory symptoms, ie, cough, dyspnea, phlegm, wheeze and recurrent lower respiratory tract infections (RLRTI) in participants with and without
COPD, respectively.
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A total of 1,185 participants (17.7%) fulﬁlled the diag-
nostic criteria for COPD, ie, respiratory symptoms,
tobacco exposure and nonreversible airﬂow limitation.
Comparison of participants with and
without COPD
On average, the participants with COPD were older, had
lower BMI and had more pack-years of smoking (Table 1).
Predictors of COPD
Among the basic characteristics, BMI was shown to be the
strongest predictor for subjects diagnosed with COPD.
This was true for subjects with BMI <25 kg/m2 and sub-
jects with BMI >35 kg/m2. Both were in reference to
subjects with a BMI between 25 and 35 kg/m2. Among
symptoms sputum, wheeze and dyspnea were found to be
signiﬁcant predictors of COPD. The severity of dyspnea
was found to be a signiﬁcant predictor of COPD as well,
measured as an MRC score of ≥3. These results are given
in Table 2.
Discussion
This was a large pooled analysis of two studies of oppor-
tunistic screening for COPD in a primary care setting. We
found that among smokers and ex-smokers, and by that at
risk for COPD, that individuals with wheeze, phlegm,
dyspnea, and a low BMI or high BMI were signiﬁcantly
more likely to be diagnosed with COPD.
Prevalence of COPD was found to be 17.7%. Other
studies such as Hansen et al and Miravitlles et al have
found a lower prevalence of COPD of 12% and 10%,
respectively.14,15 The lower prevalence reported in the
previously mentioned studies might be explained by
them including never-smokers. Never-smokers as a group
have a signiﬁcantly lower risk of being diagnosed with
COPD thereby bringing down the prevalence of the
cohort. The study by Minas et al found a prevalence of
COPD of 18.4% though almost half of the subjects in the
cohort were never-smokers.16 This, however, can be
explained by them including subjects who were previously
diagnosed with COPD in their analysis. If they had
excluded these subjects the study by Minas et al would
have reached a prevalence of 13% which is comparable to
the previously mentioned studies that included never-
smokers.14,15,16 Studies that include only ever smokers
found a similar prevalence of undiagnosed COPD as in
our study. Llordes et al17 found a prevalence of 15.5% of
undiagnosed COPD cases among ever smokers, after
excluding individuals with a previous COPD diagnosis.
Jordan et al18 found a massive prevalence of 32%
(n=662) of undiagnosed cases of COPD among individuals
who had respiratory symptoms (chronic cough, phlegm,
wheeze and exertional breathlessness) and attended spiro-
metry. A large amount of study participants (36.7%,
n=1,199) who had positive respiratory symptoms did not
attend diagnostic spirometry, and this could potentially
explain the relatively higher prevalence found vs that
found in our study.
In concordance with the present study, other studies
have found the presence of wheeze, phlegm and dyspnea
to be independent predictors of COPD.16,19 In addition to
any degree of dyspnea being a signiﬁcant predictor, it was
shown that the severity of dyspnea based on MRC score
was signiﬁcant as well. This correlates well with our
clinical understanding of COPD and is backed up by the
literature.20,21
Age was shown to be a reliable predictor of COPD, with
signiﬁcant increases in OR with each 10-year rise above 50
years as shown in several previous studies.6,16,19,21,22 Though
it should be considered if the ﬁxed FEV1/FEV-ratio enhances
this effect due to the general decline in lung function with
increasing age. A study by Roberts et al suggests using lower
limits of normalityin COPD diagnostics as the age-dependent
Table 2 Risk factors associated with new diagnosis of COPD
among 6,710 symptomatic smokers and ex-smokers identiﬁed in
general practice
Risk factor OR 95% CI p-value
Pack-years (/10) 1.06 1.03–1.09 <0.001
Symptoms
Dyspnea 1.2 1.0–1.4 0.039
Phlegm 1.3 1.1–1.6 <0.001
Wheeze 1.3 1.1–1.6 0.012
MRC score 3+ 1.6 1.2–2.0 0.001
Age
40–49 years 1.6 0.9–1.8 0.120
50–59 years 2.4 1.4–4.1 0.002
60–69 years 3.5 2.0–6.0 <0.001
≥70 years 3.9 2.2–6.7 <0.001
BMI group
<25 (kg/m2) 4.2 3.0–5.9 <0.001
>35 (kg/m2) 1.6 1.1–2.2 0.006
Note: MRC score 3+: an MRC score of 3–5 compared to an MRC score of 1–2.
Abbreviations: MRC, Medical Research Council dyspnea scale; BMI, body mass
index.
Katsimigas et al Dovepress
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decrease in FEV1/FVC-ratio tends to cause overdiagnosis of
COPD with increasing age.23
A strong association was found between COPD and BMI
<25 kg/m2. These ﬁndings are consistent with those pre-
sented by Minas et al and Price et al. Interestingly, we
found an association between obesity (BMI >35 kg/m2) and
COPD,whichwas not found in the study byMinas et al16 and
is directly contrary to the ﬁndings by Price et al.22 A potential
explanation is the sheer size of the dataset (1,185 cases) in
our study, compared to Minas et al (281 cases) and Price et al
(155 cases), which is likely to allow the signal to come
through. Another possible explanation for the differences in
ﬁndings may be the choice of reference group, as Price et al
used BMI <25 kg/m2 as the reference group and with this
found a higher COPD risk for those with a BMI >35, together
with our choice of BMI ≥25 to ≤35 kg/m2 as the reference
group compared with a higher risk of COPD in those with
BMI <25 kg/m2. Our ﬁndings are in line with ﬁndings by
Jordan et al18 who found BMI <25 kg/m2 showed a signiﬁ-
cantly increased probability of COPD.
Strengths and limitations
This was a large-scale multicenter study with almost 400
participating GPs and 6,710 screened subjects. All subjects
were screened using spirometry followed by a bronchodi-
lator reversibility test for individuals having airﬂow lim-
itation at screening spirometry, and the diagnostic workup
was, therefore, done per GOLD.13
All tests were carried out by the GP and his/her staff, and
the quality of the spirometry is therefore likely to be lower
than those performed in a respiratory outpatient clinic.
Furthermore, the GPs own equipment was used for all spiro-
metry tests. It is likely that calibration and quality checkups
are performed less regularly as well compared to an out-
patient clinic where spirometry tests are done in almost all
patients. However, general practice is the place where most
patients with possible COPD are initially examined, so the
potential bias introduced by the setup in the present study is
likely to be very close to the real-life scenario.
Conclusion
According to the present study, symptomatic smokers and
ex-smokers with dyspnea, phlegm and wheeze have a
signiﬁcantly higher risk of being diagnosed with COPD.
Furthermore, BMI <25 kg/m2, BMI >35 kg/m2, increasing
age and an increasing number of pack-years smoked were
important predictors and highlight a group of high-risk
patients that GPs should be increasingly aware of and
steps should be taken to ensure that these patients are
diagnosed in order to pave the way for early intervention.
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